JPS5767548A - Insulin analog and its preparation - Google Patents

Insulin analog and its preparation

Info

Publication number
JPS5767548A
JPS5767548A JP14403280A JP14403280A JPS5767548A JP S5767548 A JPS5767548 A JP S5767548A JP 14403280 A JP14403280 A JP 14403280A JP 14403280 A JP14403280 A JP 14403280A JP S5767548 A JPS5767548 A JP S5767548A
Authority
JP
Japan
Prior art keywords
insulin
amino acid
insulin analog
derivative
diabetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP14403280A
Other languages
Japanese (ja)
Inventor
Kazuyuki Morihara
Tatsu Oka
Yukio Shigeta
Tadashi Kobayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to JP14403280A priority Critical patent/JPS5767548A/en
Publication of JPS5767548A publication Critical patent/JPS5767548A/en
Pending legal-status Critical Current

Links

Landscapes

  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

NEW MATERIAL:An insulin analog in which the B chain at the 30-position is substituted by an amino acid or a derivative thereof.
EXAMPLE: [B30-Leucine]-hog insulin.
USE: A remedy for diabetes, particularly useful for diabetic patiens resistant to insulin. The antibody production can be reduced to a small amount by using in general diabetic partients.
PROCESS: Des-B30-insulin obtained from various animals is condensed with a desired ≥5C D- or L-amino acid or a derivative thereof to give the aimed insulin analog. The condensation reaction is carried out by using a protease having the ability to cleave the carboxyl side of a basic amino acid residue, e.g. trypsin.
COPYRIGHT: (C)1982,JPO&Japio
JP14403280A 1980-10-14 1980-10-14 Insulin analog and its preparation Pending JPS5767548A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP14403280A JPS5767548A (en) 1980-10-14 1980-10-14 Insulin analog and its preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP14403280A JPS5767548A (en) 1980-10-14 1980-10-14 Insulin analog and its preparation

Publications (1)

Publication Number Publication Date
JPS5767548A true JPS5767548A (en) 1982-04-24

Family

ID=15352735

Family Applications (1)

Application Number Title Priority Date Filing Date
JP14403280A Pending JPS5767548A (en) 1980-10-14 1980-10-14 Insulin analog and its preparation

Country Status (1)

Country Link
JP (1) JPS5767548A (en)

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0137361A2 (en) * 1983-09-23 1985-04-17 Hoechst Aktiengesellschaft Insulin derivatives modified in position B 30, process for their preparation, their vuse and pharmaceutical agents for the treatment of diabetes mellitus
EP0884053A1 (en) * 1997-06-13 1998-12-16 Eli Lilly And Company Stable insulin formulations
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
WO2001052937A1 (en) * 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1283051A1 (en) * 1997-06-13 2003-02-12 Eli Lilly And Company Stable insulin formulations
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP2033662A1 (en) 2004-01-21 2009-03-11 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2107069A2 (en) 2003-08-05 2009-10-07 Novo Nordisk A/S Novel insulin derivatives
EP2264066A2 (en) 2003-08-05 2010-12-22 Novo Nordisk A/S Novel insulin derivatives
EP2292653A1 (en) 2005-02-02 2011-03-09 Novo Nordisk A/S Novel insulin derivatives
US8710001B2 (en) 2006-07-31 2014-04-29 Novo Nordisk A/S PEGylated, extended insulins
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US9688737B2 (en) 2008-03-18 2017-06-27 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6094999A (en) * 1983-09-23 1985-05-28 ヘキスト・アクチエンゲゼルシヤフト Insulin derivative and manufacture
EP0137361B1 (en) * 1983-09-23 1990-05-16 Hoechst Aktiengesellschaft Insulin derivatives modified in position b 30, process for their preparation, their vuse and pharmaceutical agents for the treatment of diabetes mellitus
EP0137361A2 (en) * 1983-09-23 1985-04-17 Hoechst Aktiengesellschaft Insulin derivatives modified in position B 30, process for their preparation, their vuse and pharmaceutical agents for the treatment of diabetes mellitus
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6620780B2 (en) 1995-03-17 2003-09-16 Novo Nordisk A/S Insulin derivatives
US7229964B2 (en) 1995-03-17 2007-06-12 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US6034054A (en) * 1997-06-13 2000-03-07 Eli Lilly And Company Stable insulin formulations
CZ299637B6 (en) * 1997-06-13 2008-10-01 Eli Lilly And Company Stable insulin formulations
EP1283051A1 (en) * 1997-06-13 2003-02-12 Eli Lilly And Company Stable insulin formulations
US6551992B1 (en) 1997-06-13 2003-04-22 Eli Lilly And Company Stable insulin formulations
EP0884053A1 (en) * 1997-06-13 1998-12-16 Eli Lilly And Company Stable insulin formulations
WO2001052937A1 (en) * 2000-01-24 2001-07-26 Medtronic Minimed, Inc. Mixed buffer system for stabilizing polypeptide formulations
EP2264066A2 (en) 2003-08-05 2010-12-22 Novo Nordisk A/S Novel insulin derivatives
EP2107069A2 (en) 2003-08-05 2009-10-07 Novo Nordisk A/S Novel insulin derivatives
US8828923B2 (en) 2003-08-05 2014-09-09 Novo Nordisk A/S Insulin derivatives
EP2264065A2 (en) 2003-08-05 2010-12-22 Novo Nordisk A/S Novel Insulin Derivatives
EP2275439A2 (en) 2003-08-05 2011-01-19 Novo Nordisk A/S Novel insulin derivatives
EP2287184A2 (en) 2003-08-05 2011-02-23 Novo Nordisk A/S Novel insulin derivatives
EP2033662A1 (en) 2004-01-21 2009-03-11 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
EP2292653A1 (en) 2005-02-02 2011-03-09 Novo Nordisk A/S Novel insulin derivatives
USRE46170E1 (en) 2005-02-02 2016-10-04 Novo Nordisk A/S Insulin derivatives
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
US8476228B2 (en) 2005-02-02 2013-07-02 Novo Nordisk A/S Insulin derivatives
EP2256130A1 (en) 2005-02-02 2010-12-01 Novo Nordisk A/S Novel insulin derivatives
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
US8859493B2 (en) 2005-02-02 2014-10-14 Novo Nordisk A/S Insulin derivatives
US11167035B2 (en) 2005-12-28 2021-11-09 Novo Nordisk A/S Insulin compositions and method of making a composition
US8710001B2 (en) 2006-07-31 2014-04-29 Novo Nordisk A/S PEGylated, extended insulins
US9018161B2 (en) 2006-09-22 2015-04-28 Novo Nordisk A/S Protease resistant insulin analogues
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
US9688737B2 (en) 2008-03-18 2017-06-27 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US10259856B2 (en) 2008-03-18 2019-04-16 Novo Nordisk A/S Protease stabilized acylated insulin analogues
US9603904B2 (en) 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10596229B2 (en) 2010-10-27 2020-03-24 Novo Nordisk A/S Method of treating diabetes mellitus by administration, at specifically defined intervals, of a derivative of a naturally occurring insulin or insulin analogue, the derivative having a prolonged profile of action
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
US9896496B2 (en) 2013-10-07 2018-02-20 Novo Nordisk A/S Derivative of an insulin analogue
US10596231B2 (en) 2016-12-16 2020-03-24 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10265385B2 (en) 2016-12-16 2019-04-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Similar Documents

Publication Publication Date Title
JPS5767548A (en) Insulin analog and its preparation
Tager et al. Isolation of a glucagon-containing peptide: primary structure of a possible fragment of proglucagon
EP0355460A3 (en) Stabilization of somatotropins by modification of cysteine residues utilizing site directed mutagenesis or chemical derivatization
EP0055945A3 (en) Human proinsulin and analogs thereof and method of preparation by microbial polypeptide expression and conversion thereof to human insulin
SE7705432L (en) POLYPEPTIME AND SET FOR ITS PREPARATION
JPS5551422A (en) Deodorization
HUT54213A (en) Process for the enzymatic removal of n-terminal sequence of proteins
NO20021335D0 (en) C-peptide for improved production of insulin and insulin analogues
JPS5569549A (en) Novel substrate for determination of enzyme activity
JPS5524147A (en) Peptide derivative
JPS5657753A (en) Novel glucagon fragment, and its use
WOLKERSDORFER et al. Processing of chromogranins in chromaffin cell culture: effects of reserpine and α-methyl-p-tyrosine
KR840004169A (en) How to Make Insulin from Proinsulin Precursor Analogs
JPS5750948A (en) Insulin analog and preparation
Cytermann A new way to investigate the dependence of elastic moduli on the microstructure of porous materials
JPS6416799A (en) H-pth (1-34) composition and its preparation
KR950018481A (en) Enzymatic Conversion of Proteins Using Immobilized Dictiostelium Dipeptidylaminopeptidase
Fahrenkrug et al. Non-amidated forms of VIP (glycine-extended VIP and VIP-free acid) have full bioactivity on smooth muscle
JPS5446776A (en) Novel peptide
AU646047B2 (en) Sulfite overbased products and process
JPS55335A (en) Pantethine homologue and its preparation
GR3000279T3 (en) Analogues of hypocalcemic polypeptide compounds preserving the calcium content of the body, their manufacture, their use as medicaments and the compositions thereof
EP0266878A3 (en) Chemical compounds
AU6306390A (en) Antibodies against highly conserved amino acid sequences of immunogenic substances, a process for the preparation of these antibodies and the use thereof in immunoassays
ES8506597A1 (en) Des asparagine-3-calcitonin